Aplasia Treatment Market Size

Aplasia Treatment Market size is likely to register remarkable growth rate during the forecast period i.e., between 2024-2036. Aplasia is a rare genetic disorder, in which, major body parts or organs are either completely absent, or minimally present. This ranges from absence of blood cells, or lack of the ability to make new cells to absent limbs and internal organs. The lifespan of an aplasia patient ranges from a few weeks to a few years, depending on the fact that which body organ is not available. The growth of the market can be attributed to the increasing demand for treatment of aplasia, as there is no known cure for this disease. In addition to this, the increasing incidences of various genetic diseases, including all types of aplasia, are estimated to boost the market growth. According to the National Organization for Rare Disorders (NORD), in the United States approximately 500-1,000 new cases of aplastic anemia are diagnosed each year. On the other hand, the prevalence is 4-6 cases in a million in Asia, and 2-3 cases in a million in Europe.

Moreover, the growing medical R&D activities aiming to develop treatment drugs for rare diseases, along with the growing investment in the field of research, are projected to boost the aplasia treatment market growth. According to the World Bank data, 2.204% of the global GDP was spent for R&D activities in 2018.